Fourteen subjects have been on treatment for at least 2 years and eight subjects have been on treatment for more than 3 years . Preliminary data from this study suggest that Amigal continues to be generally well-tolerated . In addition , in the subset of these patients that meet the Phase 3 study entry criteria and have only received the Phase 3 dose and regimen , results suggest stabilization of renal function as measured by GFR and trends of improvement in proteinuria . The Company will provide an update from this study in the first quarter of 2010 .